share_log

RBC Capital Maintains Outperform on Karuna Therapeutics, Raises Price Target to $293

Benzinga Real-time News ·  Sep 29, 2022 07:14

RBC Capital analyst Brian Abrahams maintains Karuna Therapeutics (NASDAQ:KRTX) with a Outperform and raises the price target from $292 to $293.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment